Welcome to our dedicated page for THERMO FISHER SCIENTIFIC SEC filings (Ticker: TMO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on THERMO FISHER SCIENTIFIC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into THERMO FISHER SCIENTIFIC's regulatory disclosures and financial reporting.
Thermo Fisher Scientific Inc. insider trading plan: Reporting person Gianluca Pettiti filed to potentially sell 400 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an indicated value of $226,000.00. Prior equity acquisitions included 385 and 15 common shares from restricted stock vesting as compensation on February 23, 2024 and February 28, 2024.
Thermo Fisher Scientific reported second quarter 2026 results, with revenue of $11.99 billion, up 10% including 5% organic growth. GAAP diluted EPS was $4.68, up 9%, and adjusted EPS was $6.03, up 13%. GAAP operating income reached $2.09 billion with a 17.4% margin, while adjusted operating income was $2.73 billion with a 22.8% margin. Free cash flow for the quarter was $1,678 million.
Management highlighted stronger end-market demand and several strategic initiatives, including next-generation Orbitrap mass spectrometry platforms, the Applied Biosystems PowerFlex Thermal Cycler, and a flagship U.S. Bioprocess Design Center in Plainville, Massachusetts. The company announced a divestiture of its microbiology business and repurchased $1.0 billion of stock in the quarter. For the first half of 2026, revenue was $22,999 million with 8% growth and organic growth of 3%; GAAP diluted EPS was $9.10 and adjusted EPS was $11.47. Updated 2026 guidance will be discussed on the earnings call.
SPERLING SCOTT M reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Scott M. Sperling received a routine equity-based compensation award. He was granted 82.84 Phantom Stock Units on June 27, 2026 under the company’s Deferred Compensation Plan for Directors.
These units are credited at a price of $513.03 per unit and are convertible into Common Stock on a 1-for-1 basis. Following this grant, Sperling holds a total of 17,674.64 Phantom Stock Units. The stock units are scheduled to be distributed in shares of Common Stock when his board service ends for any reason or upon a change of control.
Keith R. Alexandra reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Keith R. Alexandra received a grant of 60.910 Phantom Stock Units on June 27, 2026 under the company’s Deferred Compensation Plan for Directors. These units are credited at $513.03 per unit and are convertible into Common Stock on a 1-for-1 basis.
Following this grant, Alexandra holds a total of 1,331.350 Phantom Stock Units, which will be distributed in shares of Common Stock after his board service ends or upon a change of control.
WEISLER DION J reported acquisition or exercise transactions in this Form 4 filing.
Thermo Fisher Scientific director Dion J. Weisler received a grant of 73.1 Phantom Stock Units. These derivative units are convertible into Common Stock on a 1-for-1 basis and were credited at a price of $513.03 per unit under the company’s Deferred Compensation Plan for Directors.
Following this award, Weisler holds a total of 2,790.99 Phantom Stock Units. According to the plan, the related shares of Common Stock are distributable after director service ends for any reason or upon a change of control.
THERMO FISHER SCIENTIFIC INC. director Karen S. Lynch received a grant of 60.910 Phantom Stock Units on Common Stock. These units were credited to her deferred compensation account at a price of $513.03 per unit under the Deferred Compensation Plan for Directors.
The Phantom Stock Units convert into Common Stock on a 1-for-1 basis and are distributable as stock when her board service ends for any reason or upon a change of control. Following this grant, her account reflects 352.400 stock units.
THERMO FISHER SCIENTIFIC INC. director Jennifer M. Johnson reported a compensation-related award of phantom stock units. She acquired 60.910 Phantom Stock Units on June 27, 2026, each convertible into one share of Common Stock, bringing her total phantom stock holdings to 722.220 units.
These units were credited at a price of $513.03 per unit under the company’s Deferred Compensation Plan for Directors, where quarterly retainers are deferred into Common Stock units based on the closing stock price at quarter end. The units are distributable as stock after she ceases serving as a director for any reason or upon a change of control.
Fidelity Brokerage Services LLC submitted a Form 144 notice listing proposed sales of common stock on 05/29/2026. The filing lists multiple tranches tied to option grants with quantities of 2,250, 9,138, 11,682, and 22,870 shares shown as to be sold on that date.
The entries reference option grant dates (09/05/2019; 02/25/2020; 02/23/2021; 09/09/2020) and indicate cash as the transaction type. The filing names Fidelity Brokerage Services LLC and lists the exchange as NYSE.
Thermo Fisher Scientific Inc. reported the results of shareholder voting from its May 20, 2026 annual meeting. All nominated directors were elected, each receiving substantially more votes "For" than "Against." For example, Debora L. Spar received 314,426,121 votes for and 311,821 against.
A key outcome was that a non-binding, advisory proposal on the compensation of the company’s named executive officers was not approved, with 99,928,178 votes for and 214,525,673 against. Shareholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, by 296,866,709 votes for and 36,064,900 against.